Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. (Q54511301)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. |
scientific article |
Statements
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. (English)
1 reference
M Elizabeth Hammond
1 reference
Daniel F Hayes
1 reference
10 May 2012
1 reference
104
1 reference
12
1 reference
957-958
1 reference
Identifiers
1 reference